Alleged excessive pricing in the pharmaceutical industry

Lear advised a pharmaceutical company, allegedly responsible for abusing its dominant position in the market by setting excessive/unfair prices for some of its products, in proceedings before the Italian Competition Authority. Lear’s analyses focused on the themes of market definition, the existence of a dominant position, measures of economic value alternative to costs and the appropriate set-up for a price-cost assessment.